30
Participants
Start Date
December 19, 2008
Primary Completion Date
August 31, 2010
Study Completion Date
July 6, 2020
Abraxane
100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
Cetuximab
400 mg/m2 IVPB, Day 1, cycle 1
Cetuximab
250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
Cisplatin
75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
5-FU
750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Radiation (Post induction)
Monday-Friday, weeks 1-7
Cisplatin
(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
Cetuximab
(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
Washington University School of Medicine, St Louis
Collaborators (1)
Celgene Corporation
INDUSTRY
Washington University School of Medicine
OTHER